Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of hAd5-S-Fusion+N-ETSD in Healthy Adults
NCT04591717Phase 1Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Oct 2020
- Primary completion
- Apr 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of hAd5-S-Fusion + N-ETSD in coronavirus disease 2019 (COVID-19) (6 cohorts), sponsored by ImmunityBio, Inc. Primary endpoints: Incidence of MAAEs and SAEs at 6 months, Incidence and severity of solicited local reactogenicity AEs at 1 week and 7 more. Started Oct 2020; status: completed.
02
Drugs
hAd5-S-Fusion + N-ETSD
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04591717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04591717.